

## Development of TYK2 pseudokinase domain selective inhibitor for autoimmune treatment

CrystalGenomics, Inc.



IMMUNOLOGY	Lead
Product Type	Chemical product
Indication	Psoriasis & Rheumatoid arthritis
Target	Tyrosine Kinase 2 (TYK2)
MoA(Mechanism of Action)	<ul style="list-style-type: none"> <li>• Selective pseudokinase inhibition of TYK2</li> <li>• Inhibition of STAT phosphorylation</li> <li>• Suppression of numerous cytokines, growth factors, and hormones in many different cells</li> <li>• Excellent target for autoimmune diseases</li> </ul>
Competitiveness	BMS-986165 (TYK2 pseudokinase domain + JAK 1/2 inhibitor) in Phase 3 is the most advanced
Differentiation Point	Currently in optimization stage to enable development of highly selective TYK2 pseudokinase domain inhibitor (IC <sub>50</sub> > 10 uM to JAK1/2) in comparison to BMS-985155 and Tofacitinib
Development Stage	Lead
Route of Administration	Oral